In this issue:
Cardiovascular disease risk in biologic recipients
Biologic treatment adherence and persistence in palmoplantar pustulosis
Biological use in older patients with immune-mediated inflammatory diseases
Tralokinumab for head and neck atopic dermatitis
Biologics and patient-reported outcomes by baseline BSA involvement
Dupilumab, tralokinumab, and upadacitinib in atopic dermatitis
Dementia risk in psoriasis patients treated with biologics
Time to disease control with dupilumab for bullous pemphigoid
Early use of beneficial biological therapy in younger psoriasis patients
Evaluating biological drugs in patients with plaque psoriasis
Please login below to download this issue (PDF)